Evidence map›Paper›PMID 38706716›Full record

ArticleFrontiers in dementia2023

Matching science to reality: how to deploy a participant-driven digital brain health platform.

Ileana De Anda-Duran, Phillip H Hwang, Zachary Thomas Popp, Spencer Low, Huitong Ding, Salman Rahman, Akwaugo Igwe, Vijaya B Kolachalama, Honghuang Lin, Rhoda Au

Abstract read
In one paragraph

Article in Frontiers in dementia, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ileana De Anda-DuranDepartment of Epidemiology, Tulane University School of Public Health and Tropical Medicine, New Orleans, LA, United States.
Phillip H HwangDepartment of Epidemiology, Boston University School of Public Health, Boston, MA, United States.
Zachary Thomas PoppDepartment of Anatomy and Neurobiology, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, United States.
Spencer LowDepartment of Anatomy and Neurobiology, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, United States.
Huitong DingDepartment of Anatomy and Neurobiology, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, United States.
Salman RahmanDepartment of Anatomy and Neurobiology, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, United States.
Akwaugo IgweDepartment of Anatomy and Neurobiology, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, United States.
Vijaya B KolachalamaBoston University Alzheimer's Disease Research Center, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, United States.
Honghuang LinDepartment of Medicine, University of Massachusetts Chan Medical School, Worcester, MA, United States.
Rhoda AuDepartment of Epidemiology, Boston University School of Public Health, Boston, MA, United States.

Funding

MRI, Genetics &Cognitive Precursors of AD &DementiaR01AG016495 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI AU, RHODA · 1999 to 2016
$12.5M
Assessing Alzheimer disease risk and heterogeneity using multimodal machine learning approachesU01AG068221 · NIA · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI DESTEFANO, ANITA L, LIN, HONGHUANG · 2021 to 2024
$2.5M
Mechanisms of drug-coated balloon therapyR01HL159620 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI KOLACHALAMA, VIJAYA B. · 2021 to 2024
$2.1M
Cognitive Heterogeneity in those with high Alzheimer's Disease RiskRF1AG062109 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI AU, RHODA · 2020 to 2021
$1.8M
Lens β-Amyloid Biomarker for Early Detection of Preclinical Alzheimer's Disease in the Framingham StudyRF1AG072589 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI GOLDSTEIN, LEE E. · 2021 to 2021
$1.7M
Cognitive heterogeneity in those with high Alzheimer's Disease RiskR01AG062109 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI Rhoda Au, Vijaya B. Kolachalama · 2025 to 2026
$1.6M
Lens β-Amyloid Biomarker for Early Detection of Preclinical Alzheimer's Disease in the Framingham StudyR01AG072589 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI LEE E. GOLDSTEIN · 2025 to 2026
$1.1M
Cognitive heterogeneity in those with high Alzheimer's Disease RiskR56AG062109 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI AU, RHODA · 2018 to 2018
$517k
PRISTINE: Pre-cancer histology identification of Endobronchial biopsies using deep learningR21CA253498 · NCI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI BEANE, JENNIFER ELLEN, KOLACHALAMA, VIJAYA B. · 2020 to 2020
$424k
Smartphone image analysis for real time adequacy assessment during kidney biopsyR43DK134273 · NIDDK · NEPHROPATHOLOGY ASSOCIATES · PI KOLACHALAMA, VIJAYA B., SHARMA, SHREE GOPAL · 2022 to 2022
$252k
NCI NIH HHS R21 CA253498NHLBI NIH HHS R01 HL159620NIA NIH HHS R01 AG016495NIA NIH HHS R01 AG062109NIA NIH HHS R01 AG072589NIA NIH HHS R56 AG062109NIA NIH HHS RF1 AG062109NIA NIH HHS RF1 AG072589NIA NIH HHS U01 AG068221NIDDK NIH HHS R43 DK134273
6 · The paper itself

Abstract

Introduction: Advances in digital technologies for health research enable opportunities for digital phenotyping of individuals in research and clinical settings. Beyond providing opportunities for advanced data analytics with data science and machine learning approaches, digital technologies offer solutions to several of the existing barriers in research practice that have resulted in biased samples. Methods: A participant-driven, precision brain health monitoring digital platform has been introduced to two longitudinal cohort studies, the Boston University Alzheimer's Disease Research Center (BU ADRC) and the Bogalusa Heart Study (BHS). The platform was developed with prioritization of digital data in native format, multiple OS, validity of derived metrics, feasibility and usability. A platform including nine remote technologies and three staff-guided digital assessments has been introduced in the BU ADRC population, including a multimodal smartphone application also introduced to the BHS population. Participants select which technologies they would like to use and can manipulate their personal platform and schedule over time. Results: Participants from the BU ADRC are using an average of 5.9 technologies to date, providing strong evidence for the usability of numerous digital technologies in older adult populations. Broad phenotyping of both cohorts is ongoing, with the collection of data spanning cognitive testing, sleep, physical activity, speech, motor activity, cardiovascular health, mood, gait, balance, and more. Several challenges in digital phenotyping implementation in the BU ADRC and the BHS have arisen, and the protocol has been revised and optimized to minimize participant burden while sustaining participant contact and support. Discussion: The importance of digital data in its native format, near real-time data access, passive participant engagement, and availability of technologies across OS has been supported by the pattern of participant technology use and adherence across cohorts. The precision brain health monitoring platform will be iteratively adjusted and improved over time. The pragmatic study design enables multimodal digital phenotyping of distinct clinically characterized cohorts in both rural and urban U.S. settings.

Indexed as

Alzheimer’s Diseasedigital phenotypingfeasibilitystudy designtechnology

Identifiers

PMID38706716
PMCPMC11067045

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.